Chutes & Ladders: Cluzel to lead Sanofi research

The shakeup at Sanofi-Aventis triggered by the decision of Jean-François Dehecq to step down as CEO will lead to the appointment of Marc Cluzel as head of research, according to a report in the Wall Street Journal. Gérard Le Fur is slated to take the CEO post as Dehecq remains chairman for three years. As number two in the research department, Cluzel has overseen much of the development of the obesity drug Acomplia, which is awaiting final action by the FDA. Sanofi now has 18 programs in late-stage development.

- here's the report on the personnel moves from The Wall Street Journal (sub req)

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.